Podcasts about Tandem

Episode #376 features Prem Sharma, Founder & CEO of Tandem. When you are a serial entrepreneur like Prem, you are probably coming up with lots of ideas but how do you decide which one is viable to focus on and actually build a company around? For Prem, it comes down to recognizing an experience that is broken and lots of market research. And this is not light market research, this is total submersion into the industry market research. The interest in Tandem started with a puppy arriving at his home as a new family pet and an experience at the vet. During a visit, he recognized how fragmented the industry was and how inefficient the office operated. This got him thinking about a unified vet experience. But, before jumping into build mode, he spent time working at veterinary clinics and recognized that the appetite for adopting a whole new system was not going to happen, so just a new tech platform wouldn't be the answer. Instead, he had to build a healthcare company from the ground up that includes a comprehensive service leveraging onsite clinics, mobile care, telehealth, and a whole new tech stack for running the overall operation. Tandem raised $10M in funding earlier this year to redefine veterinary care with a comprehensive solution through its novel approach to care delivery, AI technology, and more. Chapters: 00:00 Prem Sherma Intro 02:48 What Ideas Should You Build a Company Around? 07:00 From Childhood Dreams to Startup Realities 10:39 Navigating the Startup Landscape 14:30 The Full Story of DayToDay Health 18:16 Building Impactful Solutions in Healthcare 21:50 The Complexity of Patient Care 27:03 Lessons Learned From Building DayToDay Health 29:45 All the Details about Tandem 38:26 Current State of the Business & GTM 44:36 Advice for Building a Healthcare Company 50:00 App & Book Recommendations Episode Sponsor: As a longtime champion of the local startup ecosystem, Silicon Valley Bank supports innovative companies with the solutions and financing they need through every stage of growth. With more than 1,500 bankers and relationship advisors, and $42B in loans as of Q2 2024 – SVB delivers the right people, service and resources to support your entire financial journey. Learn more at SVB.com.

This Flashback Friday is from episode 301, published last February 21, 2013. Jason Hartman interviews Bud Conrad, Chief Economist of Casey Research, regarding the geopolitical focal points in our world, funneling these down to how it all affects the United States. Bud mentions the importance of looking at the big picture of what is happening in the world, particularly China becoming the new “mover” in the world, Japan's apparent desire to destroy its currency, new technology, government overreach, who benefits from inflationary measures and monetary policy, and much more. Author of the new book Profiting from the World's Economic Crisis, Bud Conrad holds a Bachelor of Engineering degree from Yale and an MBA from Harvard. He has held positions with IBM, CDC, Amdahl, and Tandem. Currently, he serves as a local board member of the National Association of Business Economics and teaches graduate courses in investing at Golden Gate University. Bud, a futures investor for 25 years and a full-time investor for a decade, is also a regular lecturer for American Association of Individual Investors and a frequent contributor on Fox Business News. In addition,  he produces original analysis for Casey Research, including unique charts and research on the economy and investment markets.   Follow Jason on TWITTER, INSTAGRAM & LINKEDIN Twitter.com/JasonHartmanROI Instagram.com/jasonhartman1/ Linkedin.com/in/jasonhartmaninvestor/ Call our Investment Counselors at: 1-800-HARTMAN (US) or visit: https://www.jasonhartman.com/ Free Class:  Easily get up to $250,000 in funding for real estate, business or anything else: http://JasonHartman.com/Fund CYA Protect Your Assets, Save Taxes & Estate Planning: http://JasonHartman.com/Protect Get wholesale real estate deals for investment or build a great business – Free Course: https://www.jasonhartman.com/deals Special Offer from Ron LeGrand: https://JasonHartman.com/Ron Free Mini-Book on Pandemic Investing: https://www.PandemicInvesting.com  

Put your head down and work. To Shikha Miglani, the formula is simple. With her mother and father setting a strong example, the Saarthee co-founder and CEO learned early in life that persistence can go a long way towards making the difference between success and failure. This determination has helped her throughout her career, especially when she set out on her own and tapped into her entrepreneurial spirit. Women to Watch's Sue Rocco talks with Miglani at length about the influence of her parents, and why she believes Saarthee is well-positioned to offer data and analytics solutions with the help of AI.Support this podcast at — https://redcircle.com/women-to-watch-r/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Replica del 7 APRILE 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

Replica del 4 APRILE 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

In dieser besonderen Folge von Attraktive Arbeitgeber hörst du einen inspirierenden Live-Mitschnitt des Generationentalks auf LinkedIn, den ich moderieren durfte – mit einem ganz besonderen Duo: Hans & Yvonne. Die beiden bilden seit zwei Jahren ein Generationentandem – und teilen ihre Erfahrungen, Erkenntnisse und echten Aha-Momente aus der gemeinsamen Arbeit.

Hour 2--J&J Show Thursday 4/3/25--Grizz, Ja, Chris Beard staying at Ole Miss, & Cowboys sign Joe Milton 929FM & Who is the best coaching tandem (CFB + CBB) in America? Bama or Ole Miss? full 2769 Thu, 03 Apr 2025 20:44:17 +0000 erDsTeXkuxdp5zQnILNcS6g28U0NzcLa sports Jason & John sports Hour 2--J&J Show Thursday 4/3/25--Grizz, Ja, Chris Beard staying at Ole Miss, & Cowboys sign Joe Milton 929FM & Who is the best coaching tandem (CFB + CBB) in America? Bama or Ole Miss? Local columnists and hoops insiders Jason Smith and John Martin appear daily 11am - 2pm on 929FM ESPN/680AM! 2024 © 2021 Audacy, Inc. Sports False https://player.amperwavepodcasting.com?feed-link=https%3A%2F%2Frss.amper

Hour 3--J&J Show Thursday 4/3/25--Who is the best coaching tandem (CFB + CBB) in America? Bama or Ole Miss? College Basketball transfer portal news from Louisville, UCONN, Memphis? Danny Green LIVE with J&J on Grizzlies issues, Ja and the NBA full 2588 Thu, 03 Apr 2025 20:43:00 +0000 Ys2RNTupzo75jxl9CAzsAmyPNmOHmYab sports Jason & John sports Hour 3--J&J Show Thursday 4/3/25--Who is the best coaching tandem (CFB + CBB) in America? Bama or Ole Miss? College Basketball transfer portal news from Louisville, UCONN, Memphis? Danny Green LIVE with J&J on Grizzlies issues, Ja and the NBA Local columnists and hoops insiders Jason Smith and John Martin appear daily 11am - 2pm on 929FM ESPN/680AM! 2024 © 2021 Audacy, Inc. Sports False https://player.amperwavepodcasting.com?feed-link=https%3A%2F%2Frss.amperwav

“Ease of use is what drives adoption,” Tandem Diabetes CEO John Sheridan explains to Bloomberg Intelligence about what can fuel further insulin-pump penetration. In this episode of Vanguards of Health Care, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview about Tandem’s Mobi pump, designed for discretion and simplicity, and the AI-powered Control-IQ Plus algorithm, now approved for both type 1 and type 2 diabetes. The conversation also touches on the company’s international market strategy, value-based reimbursement and future product development, including the tubeless Sigi.See omnystudio.com/listener for privacy information.

Replica del 3 APRILE 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

Show NotesBorn in Athens, Greece as an Air Force brat, Teri M. Brown now calls the North Carolina coast home. In 2020, she and her husband, Bruce, rode a tandem bicycle across the United States from Astoria, Oregon to Washington DC, successfully raising money for Toys for Tots. Her latest work, 10 Little Rules for a Double-Butted Adventure, launches February 2025 and is an inspirational look at the life lessons she learned riding across the United States on a tandem bicycle. Learn more at www.terimbrown.com.  QUOTE: "⛔ “Don't quit on a bad day. Rest, regroup, and then decide. You'll always wonder if you could've gone on.” - Teri M. BrownFergie's Top 5+ Knowledge Nuggets and Take-Aways:

Replica del 1 APRILE 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

Text Me Your Thoughts On This EpisodeIn this episode, I'm joined by Greg “Miff” Smith—a true pioneer in Australian skydiving. With nearly five decades in the sport and more than 12,000 jumps to his name, Miff has been a driving force behind the growth and evolution of skydiving in South Australia and beyond.Since making his first jump in 1977, Greg has become one of the country's most respected Chief Instructors. In 1986, alongside Gavin Northsworthy and Kevin Taylor, he helped introduce tandem skydiving to South Australia, making the sport more accessible to newcomers. Over the years, his leadership has helped advance safety protocols and raise equipment standards across the region.At SA Skydiving—founded in 1989—Greg serves as Director, Senior Pilot, Drop Zone Safety Officer, Examiner, and Instructor for both Tandem and AFF. His contributions have helped shape SA Skydiving into one of Australia's premier drop zones, offering breathtaking experiences and high-quality training.Beyond his professional achievements, Greg has mentored generations of skydivers—including his own children—creating a tight-knit community rooted in passion and progression.Join me as I speak with Greg “Miff” Smith about his journey, his impact on the sport, and the legacy he continues to build in Australian skydiving.

Replica del 31 MARZO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

Join us for an exhilarating conversation with Grinshina Kartik (known to the world as Grinny), a trailblazing ultra-cyclist who has conquered some of the toughest endurance rides across the globe—from the scorching heat of Spain and the suffocating humidity of Thailand to the freezing nights of France and the wild, winding ghat roads of India. As the first Indian woman (and often the first Indian ever) to complete grueling 2000km+ races, she's shattered records, including a world record in tandem cycling. But beyond the accolades, Grinny's journey is packed with unforgettable stories—like dodging wild elephants, outrunning packs of stray dogs, dancing on her bike to stay motivated, and pushing through brutal sunburns, crashes, and sleepless nights.In this episode, she opens up about the mental and physicalgrit it takes to thrive in ultra-cycling, the kindness of strangers in remote villages, and how she turns pain into power. Whether you're a cyclist, an adventurer, or just someone who loves underdog triumphs, Grinny's infectiousenergy and raw honesty will leave you inspired to chase your own limits. Strap in—this one's a wild ride! ---------------------------------------------Follow Grinny on Instagram ---------------------------------------------To support our team and donate generously, please click ⁠⁠⁠⁠SUPPORT ⁠⁠⁠⁠.Like our work? Follow, Like & Subscribe to our podcast from wherever you are listening in. We would also love to hear from you, so do write to us at:Email: ⁠⁠⁠⁠misadventuresofasneaker@gmail.com⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠@misadventuresofasneaker⁠⁠⁠⁠Blog: misadventuresofasneaker.substack.com---------------------------------------00:00:00 Trailer00:01:27 Episode intro00:03:54 Question from listener00:09:28 Our guest         00:10:49 Early Sports life00:19:43 Yoga-Dancing-Cycling days00:23:41 1st 100 km – exhausting 00:25:23 First Solo00:26:36 Randonneuring & Audax world Clubs00:32:59 1st 200-300-400-600 km00:43:34 Paris Brest Paris event 201900:50:02 Thailand 2000 Km LRM01:00:11 Cycle riding style01:03:34 1st cycling race01:05:16 Covid events & Everesting01:09:12 Break01:10:06 2023 Paris Brest Paris event01:12:08 Prepping & Packing for event01:20:08 Cycle, parts & repairs01:24:43 Spend time solo-cycling01:27:08 Tandem cycling – world record01:32:46 Unsupported event – Spain to Italy01:47:48 Supported event – racing in Sri Lanka01:48:54 India events01:53:22 Animal encounters02:00:03 Personal victories02:02:13 Plan ahead 02:04:08: Thanks & Toodles

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Learning more about the FDA letter sent to Dexcom, news from ATTD including a bihormonal pump from a Dutch company, time in tight range update, more studies about using insulin and GLP-1 medications, eating chili to prevent gestational diabetes (really!) and more..  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week: Dexcom Dive Brief: A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom's continuous glucose monitors. The FDA raised concerns with a design change to a component used in the resistance layer of Dexcom's sensors. The sensors with the new component were less accurate than those with the original component, according to the warning letter. Dexcom has ceased distribution of G7 sensors with the component, but the company's response did not address affected G6 sensors. J.P. Morgan analyst Robbie Marcus wrote in a research note Tuesday that the letter concerns a chemical compound that the sensor wire is dipped in. Dexcom began producing the compound internally to add redundancy to its supply chain.   Dive Insight: Dexcom Chief Operating Officer Jake Leach said in an interview with MedTech Dive last week that the company does not expect the warning letter to affect future product approvals, including a 15-day version of its G7 CGM, and there's no need yet to recall products. Dexcom has submitted the device to the FDA and anticipates a launch in the second half of the year.   Marcus, after speaking to company leadership and a quality control expert, wrote that many of the issues outlined in the letter could be addressed quickly. He added that the warning letter could explain minor delays in approval to the 15-day sensor, but Dexcom is still within the 90-day window for a 510(k) submission.   “While there's always a risk this could impede future product approvals,” Marcus wrote, “we do not expect this to materially delay the 15 day G7 sensor approval.”   The warning letter followed an FDA inspection last year of Dexcom's facilities in San Diego and Mesa, Arizona. Marcus wrote that after the FDA requested additional information and a separate 510(k), Dexcom stopped in-sourcing the compound and reverted back to the external supplier.   Dexcom's devices were misbranded because the company did not submit a premarket notification to the FDA before making major changes to the sensors, according to the warning letter. The sensors with the changed coating “cause higher risks for users who rely on the sensors to dose insulin or make other diabetes treatment decisions,” the letter said.     The FDA raised other concerns in the warning letter, including procedures to monitor the glucose and acetaminophen concentrations used in testing of the G6 and G7 CGMs. The FDA also cited problems with Dexcom's handling last year of a deficiency in its G6 sensors with dissolved oxygen content values, a key input for measuring blood glucose levels. https://www.medtechdive.com/news/dexcom-warning-letter-cgm-coating-change/743597/ XX Lots of studies and info out of the recent ATTD conference. One highlight that has been sort of under the radar: a Dutch company has been using a Bihormonal fully closed-loop system for the treatment of type 1 diabetes in the real world. This is a company called Inreda (in-RAY-duh). The Inreda AP® is an automatic system (closed loop) and independently regulates the blood glucose level by administering insulin and glucagon. The AP5 is certified in Europe and is being used in multiple studies and projects. The AP®6 is currently under development. https://www.inredadiabetic.nl/en/discover-the-ap/ https://pubmed.ncbi.nlm.nih.gov/38443309/ XX Let's talk about time in tight range. If you follow me and diabetes connections on social, you likely saw a video I made about this – it blew up last week. If not.. time in range has been a metric for a short while now.. in 2019 there was a consensus report advising a goal of 70% of time in the 70-180 mg/dL range for most people with type 1 diabetes (T1D) and type 2 diabetes (T2D), with modifications for certain subgroups. Recently we've been hearing more about 70-140 mg/dL — for longer periods as “time in tight range (TiTR).” At ATTD there was more talk about calling that range TING, or “time in normal glycemia.     There's a great writeup that I'll link up from the great Miriam Tucker on Medscape about a debate that happened at ATTD. On March 22, 2025, two endocrinologists debated this question at the Advanced Technologies & Treatments for Diabetes (ATTD) 2025. Anders L. Carlson, MD, medical director of the International Diabetes Center (IDC), Minneapolis, took the positive side, while Jeremy Pettus, MD, assistant professor of medicine at the University of California San Diego, who lives with T1D himself, argued that it's too soon.   https://www.medscape.com/viewarticle/should-time-tight-range-be-primary-diabetes-goal-2025a100073q?form=fpf   XX Sequel Med Tech announces its twist pump will be firs paired with Abbott's FreeStyle Libre 3 Plus. The twist has FDA approval for ages 6 and up and is set to begin its commercial launch by the end of June. The pump—designed by inventor Dean Kamen's Deka Research & Development—also incorporates the FDA-cleared Tidepool Loop software program, to record CGM blood sugar readings, make predictions based on trends and adjust its background insulin levels accordingly. https://www.fiercebiotech.com/medtech/sequel-med-tech-connects-twiist-insulin-pump-abbotts-cgm-ahead-market-debut XX Dexcom's longer-lasting CGM sensor looks promising, based on study results presented at the conference. The trial showed that the new 15-day G7 system is slightly more accurate than the current G7. The accuracy of CGM can be measured using MARD (mean absolute relative difference), which shows the average amount a CGM sensor varies from your actual glucose levels (a lower number is better).  The 15-day G7 has a MARD value of 8.0%, about the same as the Abbott Freestyle Libre 3. The Dexcom G7 15 Day is awaiting FDA approval and is not yet available in the U.S.   XX Little bit of news from Modular Medical.. they plan to submit their patch pump to the FDA late summer or fall of this year. The MODD1 product, a 90-day patch pump, features new microfluidics technology to allow for the low-cost pumping of insulin. Its new intuitive design makes the product simple to use and easier to prescribe. It has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery. Modular Medical picked up FDA clearance for MODD1 in September. The company also raised $8 million to end 2024. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. By developing its patented insulin delivery technologies, the company hopes to improve access to glycemic control. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. https://www.drugdeliverybusiness.com/modular-medical-announces-12m-private-placement/ XX More from attd – type 2 news? https://www.drugdeliverybusiness.com/biggest-diabetes-tech-news-attd-2025/ XX Another study that says people with type 1 who use a GLP-1 medication get better outcomes. In this study, those who use GLP-1 with insulin are 55% less likely to have a hyperglycemia-related ED visit, 26% less likely to have an amputation-related visit, and 29% less likely to have a diabetic ketoacidosis (DKA)-related ED visit in the following year compared to those on insulin alone. Although they are not approved for T1D, some patients may receive them off-label or for weight control. Pretty big study for an off label drug: compared 7,010 adult patients with T1D who were prescribed GLP-1s and insulin to 304,422 adult patients with T1D who were on insulin alone.  It is important to note that the rates of new diabetic complications in one year for both groups were around 1%, indicating that these are uncommon outcomes regardless of medication use. https://www.epicresearch.org/articles/some-diabetic-complications-less-likely-among-type-1-diabetics-on-glp-1s   XX Early research here but exposure to antibiotics during a key developmental window in infancy may stunt the growth of insulin-producing cells in the pancreas and boost risk of diabetes later in life The study, is published this month in the journal Science, it's a study in mice. These researchers are working off the idea that when while identical twins share DNA that predisposes them to Type 1 diabetes, only one twin usually gets the disease. She explained that human babies are born with a small amount of pancreatic “beta cells,” the only cells in the body that produce insulin.   But some time in a baby's first year, a once-in-a-lifetime surge in beta cell growth occurs.   “If, for whatever reason, we don't undergo this event of expansion and proliferation, that can be a cause of diabetes,” Hill said.   They found that when they gave broad-spectrum antibiotics to mice during a specific window (the human equivalent of about 7 to 12 months of life), the mice developed fewer insulin producing cells, higher blood sugar levels, lower insulin levels and generally worse metabolic function in adulthood.   in other experiments, the scientists gave specific microbes to mice, and found that several they increased their production of beta cells and boosted insulin levels in the blood. When male mice that were genetically predisposed to Type 1 diabetes were colonized with the fungus in infancy, they developed diabetes less than 15% of the time. Males that didn't receive the fungus got diabetes 90% of the time. Even more promising, when researchers gave the fungus to adult mice whose insulin-producing cells had been killed off, those cells regenerated. Hill stresses that she is not “anti-antibiotics.” But she does imagine a day when doctors could give microbe-based drugs or supplements alongside antibiotics to replace the metabolism-supporting bugs they inadvertently kill.   .   “Historically we have interpreted germs as something we want to avoid, but we probably have way more beneficial microbes than pathogens,” she said. “By harnessing their power, we can do a lot to benefit human health.”     https://www.eurekalert.org/news-releases/1078112 XX Future watch for something called BeaGL - created by researchers at the University of California Davis and UC Davis Health who were inspired by their own personal experiences with managing T1D.   BeaGL is designed to work with CGMs and has security-focused machine learning algorithms to make predictive alerts about anticipated glucose changes, which are sent to a device. In this case, a smartwatch. The end goal is for BeaGL to be completely automated to reduce the cognitive load on the patient, particularly for teens. It's still in research phase but six student with T1D have been using it for almost a year.     https://health.ucdavis.edu/news/headlines/with-ai-a-new-metabolic-watchdog-takes-diabetes-care-from-burden-to-balance/2025/02 XX Investigators are searching for a way forward after two long-term diabetes programs were terminated following the cancellation of their National Institutes of Health (NIH) funding, the result of federal allegations that study coordinator Columbia University had inappropriately handled antisemitism on campus. The programs include the three-decades-old Diabetes Prevention Program (DPP) and its offshoot, the Diabetes Prevention Program Outcomes Study (DPPOS). “We are reeling,” said David Nathan, MD, a previous chair of both the DPP and the DPPOS and an original leader of the landmark Diabetes Control and Complications Trial. Nathan is also founder of the Massachusetts General Hospital Diabetes Center in Boston, one of the 30 DPPOS sites in 21 states. On March 7, the Trump administration cancelled $400 million in awards to Columbia University from various federal agencies. While Columbia University agreed on March 21 to changes in policies and procedures to respond to the Trump administration's charges, in the hopes that the funding would be restored, DPPOS Principal Investigator Jose Luchsinger, MD, told Medscape Medical News that as of press time, the study was still cancelled. https://www.medscape.com/viewarticle/diabetes-prevention-program-cancellation-colossal-waste-2025a100076h XX XX Type 2 diabetes may quietly alter the brain in ways that mimic early Alzheimer's. This was only an animal study – but researchers say the high comorbidity of type 2 diabetes (T2D) with psychiatric or neurodegenerative disorders points to a need for understanding what links these diseases.   https://scitechdaily.com/how-diabetes-quietly-rewires-the-brains-reward-and-memory-system/ XX Eating chili once a month when you're pregnant seems to lower the risk of developing gestational diabetes. This is a real study! While chili showed a link to lower gestational diabetes risk, dried beans and bean soup had no significant effect, even among women who ate them more frequently. Some studies suggest that diets high in beans and legumes, including the Mediterranean diet, reduce GDM risk. While studies link beans to lower diabetes risk, their specific impact on GDM remains unclear. This study analyzed data from 1,397 U.S. pregnant women who participated in the Infant Feeding Practices Study II, conducted between 2005 and 2007. Chili consumption varied significantly by race, education, household size, income, supplemental nutrition status, and region. Non-Hispanic Black mothers consumed the most (0.33 cups/week), while those with higher income and education levels consumed less. Regional differences also influenced chili intake. One possible mechanism for chili's effect is capsaicin, a bioactive compound found in chili peppers, which has been linked to metabolic benefits in other studies. However, further research is needed to confirm this potential role in GDM prevention. Dried bean and bean soup consumption had no clear association with GDM. The study highlights limitations due to self-reported dietary data and the need for more detailed dietary measures. https://www.news-medical.net/news/20250317/Could-a-little-spice-in-your-diet-prevent-gestational-diabetes.aspx XX

Replica del 28 MARZO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

What happens when you take a bike built for two and bring it to some of the most rugged, remote and challenging bikepacking in the world? You get tandemonium, and honestly, Shona and Rich Oldfield wouldn't have it any other way. Shona and Rich live in Manchester, UK, where they run Keep Pedalling, a small but mighty bike shop dedicated to supplying help, advice, and bikes for adventures. Over the past decade, they've quietly become legends in the bikepack racing world — not for winning races, but for how they show up: almost always together, and usually on a tandem. It's long, it's heavy, and by most standards absolutely the “wrong” bike for these races — which, of course, makes it perfect for them. In this episode, we talk about what it's actually like to race a tandem off-road: how they divide roles on the bike, what happens when one of them wants to sleep (and the other doesn't), and why Rich refuses to use the brakes. They also share some wild hallucination stories, dog packing with their pup Olive, and how the tandem has become a symbol of their approach to life: good-humoured, stubborn, and quietly joyful. Shona and Rich remind us that these events are supposed to be fun, and that there's no “right” way to do these things, just the way that works for you. As always, thanks to Albion Cycling for supporting the podcast this year.Follow Shona and Rich on Instagram: @keep_pedallingFollow Mel on Instagram: @melwwebbFollow Detours on Instagram: @detourspodcastFollow Albion on Instagram: @albion.cycling Hosted on Acast. See acast.com/privacy for more information.

In this episode, I'm joined by Robert and Kay Lee Fukui, founders of Married Entrepreneurs and authors of Tandem: The Married Entrepreneur's Guide for Greater Work-Life Balance. They share invaluable insights on how to balance business and marriage, avoid financial stress, and prevent the power struggle between entrepreneurship and relationships. Whether you're running a business with your spouse or managing work-life balance as a solopreneur, this episode is full of practical strategies to help you thrive in both business and marriage. What You'll Learn in This Episode: ✅ The impact of business on marriage and how to keep it from becoming the "mistress" in the relationship ✅ How to set boundaries when working from home to protect your personal life ✅ The importance of weekly meetings for better communication and alignment in your marriage and business ✅ How to get spousal support for your business, even if they're not directly involved ✅ The role of love languages in business and marriage success Timestamps (00:00) Welcome & Guest Intro – Meet Robert & Kay Lee Fukui, their background, and their book Tandem (03:00) The “Business as the Mistress” Problem – Why many entrepreneurial couples struggle with work-life balance (06:30) Early Signs of Business Overpowering Your Marriage – What to look for before it becomes an issue (08:45) Setting Boundaries When Working From Home – Simple strategies to separate work and personal life (15:00) The Power of a Weekly Meeting – How one structured conversation can save your business and marriage (20:45) Navigating the “Side Hustle” Mindset Shift – Why some spouses don't take your business seriously & how to change that (27:00) Understanding Spousal Support Needs – The crucial difference between emotional and practical support (34:30) Final Thoughts & Where to Find Robert & Kay Lee Resources & Links

Replica del 26 MARZO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

Replica del 25 MARZO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem! Oggi hanno pedalato insieme al piccolo Matteo...che ha portato una super merenda!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

TSN Hockey Insider Chris Johnston joined OverDrive to discuss the headlines around the NHL, the standings race for the Stanley Cup Playoffs, Sheldon Keefe calling out Johnathan Kovacevic, Morgan Rielly's tough season, the Maple Leafs' tandem decisions, Auston Matthews' ability to lead the team and more.

Replica del 24 MARZO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

Tandem means walking together in alignment. Faith often requires walking in tandem with the Lord—hearing His direction and responding with obedience. When He says "Go," you actually go. What many heroes of faith had in common was their willingness to walk in obedience to God. Listen and learn just how to walk in tandem with the Lord.

Replica del 21 MARZO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

Ecoutez Ecran Total avec Isabelle Morini-Bosc du 21 mars 2025.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

TSN Hockey Analyst Frank Corrado joined OverDrive to discuss the headlines around the NHL, the Maple Leafs' roster overview, the goaltending tandem with Joseph Woll and Anthony Stolarz and the playoff role, the Hart Trophy race in the NHL and more.

Replica del 20 MARZO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

Some changes coming to Tandem's Control IQ software… which will now be called Control IQ Plus. What have they added? I'm talking with Dr. Laurel Messer, senior director of Medical Affairs at Tandem to answer your questions about this software update, type 2 indication, whatever happened to Tandem's new infusion sets and reusable patch pump, and lots more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Important Safety Information: RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older and for patients with type 2 diabetes, 18 years and older. BOXED WARNING: Control-IQ+ technology should not be used in anyone under the age of 2 years old with type 1 diabetes or under the age of 18 years old with type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds, as those are the required minimum values needed for Control-IQ+ to operate safely. Safety info: tandemdiabetes.com/safetyinfo.    Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

-CBS Sports listed the Top 10 tandems of coaches in college sports for football and men's basketball, and Kansas---yes, formerly lowly Kansas (at least in football)---is No. 1 (!!) with Bill Self and friend-of-the-show Lance Leipold. Great for them, sad for Nebraska-Others on the list in order: Alabama (Nate Oats/Kalen DeBoer); Iowa State (TJ Otzelberger/Matt Campbell); Tennessee (Josh Heupel/Rick Barnes); Clemson (Brad Brownell/Dabo Swinney); Oregon (Dan Lanning/Dana Altman); Michigan State (Tom Izzo/Jonathan Smith); UConn (Jim Mora, Jr./Dan Hurley); Baylor (Dave Aranda/Scott Drew); and Houston (Willie Fritz/Kelvin Sampson)-Knowing how much Nebraska pays its head coaches…some of these are PAINFUL to look at…Iowa State and Kansas?!Show sponsored by MIDWEST BANKOur Sponsors:* Check out Hims: https://hims.com/EARLYBREAKAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Replica del 18 MARZO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

Scott Wharton is a visionary entrepreneur and CEO making waves in the solar industry as the leader of Tandem PV, where he's developing solar cells that are about 30% more efficient than current market options. Previously, he spent eight years at Logitech as a general manager, revolutionizing how businesses use consumer tech for productivity and collaboration. Before that, he was the CEO of Vidtel, which was acquired by Fidelity Investments in 2013. A bold thinker and risk-taker, Scott is known for his leadership and innovation across industries. He holds an MBA from Yale and a bachelor's degree from Binghamton University.In this conversation, we discuss:How solar energy has become the cheapest and most scalable power source —and why most people haven't caught up to this reality.The breakthrough potential of perovskite solar cells and why they're set to replace silicon as the industry standard.Why the U.S. must invest in solar manufacturing – and how bringing production back from China strengthens energy security.The evolving synergy between solar and battery storage —how new advancements are making 24/7 renewable power a reality.Common myths about solar's limitations and why concerns about cost, reliability, and land use no longer hold up.Scott's journey from leading video conferencing at Logitech to revolutionizing the solar industry – and what motivated him to take on this challenge.Resources:Subscribe to the AI & The Future of Work Newsletter:  https://aiandwork.beehiiv.com/subscribe Connect with Scott Wharton on LinkedIn:  https://www.linkedin.com/in/scottwharton/AI fun fact article: https://www.cnbc.com/2024/11/23/data-centers-powering-ai-could-use-more-electricity-than-entire-cities.html On how AI can be used to provide fact-based impartial answers to scientific questions: https://www.buzzsprout.com/520474/episodes/11574063 

Replica del 17 MARZO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

HELLOOOO!!! we finished the tandem read holy cow. Thoughts?? SOrrows?? Prayers??Let's hop right into Kingdom of Ash shall we? Grab tissues, grab a drink, and let's dive in. Do not forget, we are switching our episode schedule to every other Saturday! Big change but we believe in quality over quantity and hopefully more time for our tipsy readers to read along with us.

Replica del 14 MARZO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

Replica del 13 MARZO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

durée : 01:28:33 - En pistes ! du mercredi 12 mars 2025 - par : Emilie Munera, Rodolphe Bruneau Boulmier - Au programme ce matin, de la musique en dialogue avec l'opéra Iphigénie en Tauride de Desmarest et Campra, les voix d'I Gemelli dans les Vêpres de Monteverdi ou le duo David Haroutunian et Xénia Maliarevitch

durée : 01:28:33 - En pistes ! du mercredi 12 mars 2025 - par : Emilie Munera, Rodolphe Bruneau Boulmier - Au programme ce matin, de la musique en dialogue avec l'opéra Iphigénie en Tauride de Desmarest et Campra, les voix d'I Gemelli dans les Vêpres de Monteverdi ou le duo David Haroutunian et Xénia Maliarevitch

Replica del 12 MARZO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

In this episode, I share my personal journey of figuring out which insulin pump works best for me and why I ultimately chose the DIY Loop. If you're considering an insulin pump or thinking about switching systems, this episode gives you an honest look at the pros and cons of different pumps like Omnipod, Tandem, and the Loop, plus how it all fits into managing your diabetes more effectively!   Want the best blood sugars you've ever had while enjoying great food? Peep this: https://www.yourdiabetesinsider.com/coaching   RESOURCES: Download these FREE guides that will help you on your diabetes, nutrition, and exercise journey! https://www.yourdiabetesinsider.com/free-stuff Join our EXCLUSIVE Facebook group! https://www.facebook.com/groups/266766620895432 Watch my food breakdowns here → https://www.youtube.com/@yourdiabetesinsider   LET'S TALK! Instagram: @manoftzeel Tiktok: @manoftzeel  

NHL on TNT Darren Pang joined OverDrive to discuss the headlines around the NHL, Connor Bedard's impending contract with the Blackhawks, Seth Jones's fit with the Panthers, Alex Ovechkin's goal scoring run. and the Capitals' solid season, the Maple Leafs' tandem, the teams under the radar in the NHL and more.

Today on the Online for Authors podcast, special guest host Carol Pearson is flipping the script and interviewing me, Teri M Brown, author of the book 10 Little Rules for a Double-Butted Adventure.   Carol Pearson is the founder of indie publishing house 10 Little Rules, creating books filled with personal narrative and guided journaling inspiration. The books are written by a growing community of authentic and inspiring authors who share their stories to empower others and share their wisdom. At 10LRs we believe in the unbreakable connection between all of us, and relish those "me too" moments that lead to insights and powerful change.   As an author of character-driven fiction, my goal is to introduce readers to characters they'd love to invite to lunch. I do this through my writing (Sunflowers Beneath the Snow, An Enemy Like Me, Daughters of Green Mountain Gap, and 10 Little Rules for a Double-Butted Adventure), through my book reviews on my blog (www.terimbrown.com/blog), and through my podcasting as host of this show.   In addition to telling a great story, I want those who read or hear my words to contemplate difficult aspects of life such as racism, xenophobia, fear of change, family dynamics, loss, and war. My TEDx talk relates my experiences with racism (https://www.youtube.com/watch?v=hxYidJsL_Wc), while my books always tackle hard topics.   In their book review, the Book Commentary stated that 10 Little Rules for a Double-Butted Adventure by Teri M Brown is a wonderful exploration of personal growth, transformation, and the quest for adventure. The book is an inspiring guide wrapped around the author's journey of cycling across the United States on a tandem bike with her husband, Bruce. Through this adventure, Brown discovers new geographical locations and insights about herself, her relationships, and life at large. She shares those insights in this life-transforming book! The book's central message is about embracing life's challenges and uncertainties to foster personal growth and healing. Brown emphasizes that everyone can achieve extraordinary feats, regardless of age or circumstances, if they break it into manageable segments and stay focused. Her tale is not just about the physical act of cycling but signifies a mental and emotional metamorphosis that empowers her to redefine her potential.    Subscribe to Online for Authors to learn about more great books! https://www.youtube.com/@onlineforauthors?sub_confirmation=1   Join the Novels N Latte Book Club community to discuss this and other books with like-minded readers: https://www.facebook.com/groups/3576519880426290   You can follow Guest-Host Carol Pearson Website: https://10littlerules.com/ FB:@10 Little Rules IG: @10littlerules LinkedIn: @10 Little Rules   Purchase 10 Little Rules for a Double-Butted Adventure on Amazon: https://10littlerules.com/   Teri M Brown, Author and Podcast Host: https://www.terimbrown.com FB: @TeriMBrownAuthor IG: @terimbrown_author X: @terimbrown1   #terimbrown.com #10littlerules #doublebuttedadventure #memoir #inspirational #selfhelp #guidedjournaling #terimbrownauthor #authorpodcast #onlineforauthors #characterdriven #researchjunkie #awardwinningauthor #podcasthost #podcast #readerpodcast #bookpodcast #writerpodcast #author #books #goodreads #bookclub #fiction #writer #bookreview *As an Amazon Associate I earn from qualifying purchases.

The Athletic Senior Writer James Mirtle joined OverDrive to discuss the headlines around the Maple Leafs, the team's trade deadline priorities, the best needs for the roster, potential trade assets to bolster the lineup, the goaltending tandem choices and more.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: New drug is looked at for T1D prevention, a new stem cell method is tested for beta cell transplanation without immunosuppresion drugs, the FDA okays the first fast-acting biosimilar insulin, Lilly lowers price of Zepbound, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX New research in type 1 diabetes prevention launches. Nektar Therapeutics and TrialNet will evaluate a drug currently used for exzema for patients with new onset stage 3 type 1 diabetes The drug is RezPeg – that's a shortened version of the name (rezpegaldesleukin)   This will be a study of about 70 adults and children and will launch this year. The new study will use a mixed meal tolerance test (MMTT) to measure the efficacy of rezpegaldesleukin or placebo for preserving C-peptide area under the curve over a 12-month duration comprised of a 6-month treatment period and a 6-month follow-up. Secondary objectives include pharmacokinetics, pharmacodynamics, and additional disease assessments including HbA1c levels and patient insulin requirements. Rezpegaldesleukin is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases. https://www.prnewswire.com/news-releases/nektar-announces-clinical-trial-agreement-to-evaluate-rezpegaldesleukin-in-patients-with-new-onset-type-1-diabetes-mellitus-302383052.html XX NLS Pharmaceutics (NLSP) and Kadimastem announced successful completion of a pre-IND meeting with the FDA for iTOL-102, a potential diabetes treatment. iTOL-102 combines Kadimastem's IsletRx cells (stem cell-derived pancreatic islets) with iTolerance's immunomodulator iTOL-100, aiming to cure Type 1 Diabetes without requiring life-long immune suppression. The treatment was evaluated at the Diabetes Research Institute at the University of Miami School of Medicine, where it demonstrated functional insulin release and disease reversal in animal models. Based on FDA feedback, the companies are updating plans for safety toxicology studies and First-in-Human clinical trials. IsletRx is a clinical-grade product comprising human pancreatic islet-like cells capable of secreting insulin, offering a scalable source of insulin-producing cells to address donor islet shortages. The technology can detect glucose levels and produce required amounts of insulin and glucagon.   XX FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has given a thumbs up to Sanofi's Merilog (insulin-aspart-szjj) as the first biosimilar to Novo Nordisk's NovoLog for patients with diabetes. Merilog will be provided by prefilled pen in a 3 mL dose or in a multiple-dose 10 mL vial. It is for adults and pediatric patients age 6 and older.     NovoLog and Novo Nordisk's other rapid-acting insulin follow-on Fiasp are among the drugs subject to government price negotiations under the Inflation Reduction Act. The new prices will be enacted at the start of next year. In July 2021, the FDA approved Biocon and Viatris' Semglee (insulin glargine-yfgn) as the first biosimilar to Lantus. Five months later, the U.S. regulator endorsed Eli Lilly's version of the drug, called Rezvoglar (insulin glargine-aglr). https://www.fiercepharma.com/pharma/fda-signs-sanofis-biosimilar-first-novo-nordisks-rapid-acting-novolog XX Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. The company launched 7.5 mg and 10 mg vials of tirzepatide, sold under the brand name Zepbound, which typically cost $599 and $699, respectively. However, they are now available for $499 per month for patients paying without insurance. This applies to the first fill and all refills that are delivered every 45 days. Additionally, the company lowered the prices of the 2.5 mg and 5 mg vials to $349 and $499 per month, respectively. The company, which has seen a significant boost in profits from Zepbound and Mounjaro – essentially the same drug with different FDA-approved uses – announced that the new vials and pricing are exclusively available through the company's self-pay pharmacy, LillyDirect Self Pay Pharmacy Solutions. https://www.bloomberg.com/news/articles/2025-02-25/zepbound-cost-for-vials-cut-to-battle-cheaper-copycats XX Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a five-year period and could reach $102 billion next year, an analysis by Health and Human Services' inspector general found. The findings also come as the Trump administration weighs the fate of a Biden administration proposal that would require Medicare and Medicaid to cover GLP-1s for weight loss. The biggest spikes in usage were for Rybelsus, Novo Nordisk's once-daily GLP-1 tablet, and for the company's weekly injectable Ozempic, whose spending about doubled every year under review. https://www.axios.com/2025/02/25/medicare-spending-surge-diabetes-drugs XX Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up Control IQ for use in adults with Type 2 diabetes. The expanded label was based on data from a pivotal, randomized trial of more than 300 people with Type 2 diabetes, comparing its use to manual multiple daily injections. Tandem said it plans to present the study's results at the annual Advanced Technologies & Treatments for Diabetes meeting scheduled for next month in Amsterdam. https://www.fiercebiotech.com/medtech/tandem-diabetes-care-insulin-dosing-algorithm-nets-fda-clearance-type-2-diabetes XX Drugs approved for diabetes and obesity might be useful for the treatment of cognitive and mental health disorders, according to a new paper published in Nature Mental Health.   The study reviewed and integrated data from both preclinical and clinical studies to gather evidence on the possible effects of these drugs GLP1s and semaglutide  in conditions such as dementia, substance use disorders, psychotic disorders, mood and anxiety disorders, and eating disorders.     The study found promising but still preliminary evidence that GLP-1RAs could be beneficial over a range of cognitive and mental health disorders. These drugs have shown potential in improving cognition, reducing addictive behavior, and alleviating depression and anxiety. More data from robustly designed studies (i.e., randomized controlled trials) are needed to better understand GLP-1RAs' prospective efficacy and safety profile, especially with long-term use. https://medicalxpress.com/news/2025-02-diabetes-drugs-mental-health-treatment.html XX The FDA  issued draft guidance that includes recommendations to support the development and marketing of safe and effective AI-enabled The guidance, if finalized, would be the first guidance to provide comprehensive recommendations for AI-enabled devices throughout the total product lifecycle, providing developers with an accessible set of considerations that tie together design, development, maintenance, and documentation recommendations to help ensure the safety and effectiveness of AI-enabled devices. FDA is requesting public comment on this draft guidance by April 7. The agency also released draft guidance for the use of AI to support regulatory decision-making for drug and biological products. https://www.mddionline.com/artificial-intelligence/fda-issues-draft-guidance-for-ai-enabled-devices-seeks-public-feedback XX Congrats to Mila Clarke who some of you may know better as Hangry Woman on social. She has developed a great app called Glucose Guide and the Nutrition Assistant portion of that app went live this week. Glucose Guide is a web and mobile app that offers diabetes meal tracking, coaching, resources, recipes and community to those looking for help managing diabetes. MEAL AND BLOOD SUGAR TRACKING FEATURES.

Can you believe we are almost done????This week's episode drink is in honor of Manon. Check out our instagram for the details.

We're back with Episode 19 of Tandem Talk – for having nothing to say, we sure do have a lot to talk about! Tune in as we discuss the unprecedented levels of market narrowness and overconcentration investors are faced with today. What has happened to the S&P 500? Are markets changed forever? Is it really different “this time”? If history (or probability) is any indication, it's not. Later, we revisit the “Lost Decade” of the aughts, and recount lessons learned. The takeaway is quite simple: if you invest like everyone else, during boom times you will boom, and during bust expect to bust. But hard times in the index does not mean hard times for all stocks, or all investors either.

Over the past half-century, USAID has frequently advanced US interests under the guise of humanitarian crisis relief.  

The BlindShell Classic 3 is here. This latest version of the popular accessible phone for the blind and visually impaired comes packed with major upgrades, including a touchscreen for select apps, a faster processor, and a brand-new AI assistant, Luna. Plus, we're diving into Tandem, the exclusive BlindShell app that makes communication easier than ever. New Features: - Touchscreen support for select third-party apps - Luna AI Assistant for voice commands and general knowledge - Tandem App for messaging, video calls, and remote support - Upgraded performance with 3GB RAM and 32GB storage - New design and colors (Golden Sand and Ocean Blue) If you're looking for an accessible, easy-to-use cell phone with physical buttons and a simple interface, this might be the perfect choice. Watch the full review to see all the features in action. Get yours here: ► https://www.blindshell.com/ Check out my BlindShell Classic 2 review: ► https://youtu.be/5r9V_UsJ6ng?si=2Y9Bl3QOq27lG7GR #BlindShellClassic3 #AccessibleTechnology #AssistiveTech #BlindLife #LowVision #VisuallyImpaired #AdaptiveTechnology #TechForAll #AIAssistant #TandemApp

Is running back making a comeback? Last year some bell cow backs like Ashton Jeanty, Cam Skattebo and Dylan Sampson carried their teams to the CFP while Ohio State, Penn St, and Notre Dame relied more on a tandem backfield. McElroy asks if it is more important to win a national championship with a “bell cow” or a deep running back room. Plus Ohio State has a new defensive coordinator what impact will Matt Patricia have, will the Texas offense look different under Arch Manning and why can't the FBS just adopt the FCS playoff model. Learn more about your ad choices. Visit podcastchoices.com/adchoices